A sabon gwaji mai ƙunshe da rarrabawa daga Asibitin Jami'ar Kasa ta Taiwan an samu bayanai masu amfani game da wannan haɗin kari. A cikin manya da aka tantance da sarcopenia ta ƙwarai, wani tsari da ke ɗauke da creatine, furotin mai yawan leucine da triglycerides na sarkar tsaka‑tsaki (MCT) ya ƙara ƙimar tsoka a cikin makonni takwas kaɗai, ba tare da wani shirin motsa jiki ba. Sai dai ƙarin ya yi ƙanƙanta, kuma bai haifar da bambanci mai mahimmanci a ƙarfi idan aka kwatanta da placebo.
Abin Da Gwajin Ya Gwada
Wannan binciken da aka wallafa a mujallar Life a watan Agusta 2026 ta hanyar Chan da abokan aiki, ya haɗa manya 73 da matsakaicin shekaru 77.3 ± 7.7, waɗanda suka cika ka’idojin Asian Working Group for Sarcopenia (AWGS) na 2019. An rarraba mahalarta cikin rukuni biyu ta hanyar gwajin double‑blind: rukunin da ya samu kari mai suna TLN‑01 (n = 34) da kuma rukunin da ya karɓi placebo mai adadin kalori iri ɗaya (n = 39).
TLN‑01 ba kawai haɗin creatine‑leucine ba ne. Bisa ga takaitaccen bayanin, ya ƙunshi:
- Whey protein
- Branched‑chain amino acids (madadin leucine)
- Medium‑chain triglycerides
- Creatine
- Resveratrol
- Vitamin D3
Manufar farko ita ce auna appendicular skeletal muscle mass (ASM) ta hanyar DXA da kuma ƙarfi na rike ƙwayar hannu. An kuma yi ƙoƙarin tantance plasma amino acid a matsayin ƙari na binciken.
Sakamakon Tsoka: Gaskiya, Amma Karami
ASM ya ƙaru da kilogram 0.42 (+3.2 %) a rukunin da ya samu kari (p < 0.001), yayin da babu wani canji a rukunin placebo (p = 0.785). Bambancin tsakanin rukunin biyu ya kasance da muhimmanci a ƙididdiga (ANCOVA p < 0.01). Samun ƙarin tsoka a cikin makonni takwas a tsakanin mutane masu shekaru 77 da ba su yin horo, ba abu ne mai sauƙi ba.
Masu binciken sun jaddada cewa canjin ya ƙasa da minimal clinically important difference (MCID) da aka saba ambata. Wato, duk da cewa canjin ya kasance tabbatacce a ƙididdiga, ba ya da girman da zai sa mutum ya yi sauri a tafiya, ya tashi daga kujerar da sauƙi, ko ya rage faɗuwar ƙasa. Wannan alama ce cewa abin ya yi tasiri a matakin halittar jiki, ba a tabbatar da tasiri a aikin yau da kullum ba.
Ƙarfi: Rashin Bambanci Mai Mahimmanci
Ƙarfi na rike ƙwayar hannu bai nuna bambanci mai ƙarfi tsakanin rukunin biyu ba (p = 0.32). Wannan shi ne babban ƙalubale ga duk wanda ke fatan foda za ta maye gurbin horo.
Bayanan cikin‑rukunin suna nuna wasu ƙananan bambance‑bambance. Mahalarta da suka samu placebo sun rasa kusan kashi 7 % na ƙarfinsu a cikin makonni takwas (p < 0.001), yayin da rukunin da ya samu kari ba su ga wani raguwa mai ma’ana ba (p = 0.537). Masu binciken sun fassara wannan a matsayin kari na rage raguwa. Wannan na da yiwuwar gaskiya, amma ba shi ne hujja kai tsaye ba; gwajin tsakanin rukunin biyu bai nuna bambanci ba, kuma canje‑canjen cikin‑rukunin ba su da ƙarfi kamar gwajin tsakanin rukunin.
Metabolomics: Ba Sha’awa, Ba Tabbas
Binciken plasma da aka yi a matsayin ƙari ya gano ƙarancin taurine da 1‑methylhistidine da kuma ƙarin kynurenine a rukunin da ya samu kari. Ƙarancin 1‑methylhistidine na iya nuni da ragin fashewar furotin na tsoka, domin wannan alamar tana da alaka da cin nama da sauyin tsoka. Sai dai samfuran PCA da PLS‑DA ba su nuna bambanci bayyananne tsakanin rukunin ba. Masu binciken sun bayyana waɗannan sakamakon a matsayin “hypothesis‑generating” kuma ba su ɗauki matsayin hujja ba.
A fannin aminci, ba a samu wani mummunan sakamako na kwayoyin halitta ko na ƙoda ba, wanda ke da matuƙar muhimmanci a cikin al’umma mafi tsufa da ke da matsalar ƙoda, musamman idan aka yi amfani da creatine da yawan furotin.
Me Yasa Shekaru Da Tsawon Gwaji Suke da Mahimmanci
Sarcopenia na shafar sama da kashi 20 % na manya a Taiwan, kuma tana haifar da rauni da ragin aiki. Mafi yawan waɗannan marasa lafiya ba za su iya kammala shirin motsa jiki na tsari ba saboda iyakokin motsi, ciwo, matsalolin tunani ko rashin lafiya. Don haka, abinci na iya zama hanya mafi amfani, don haka nuna wani tasiri ba tare da motsa jiki ba yana da ƙima.
Akwai iyakokin da suka haɗa da: cibiyar gwaji guda ɗaya, tsawon makonni takwas, mahalarta 73, da kuma tsari da ke ɗauke da sinadarai da dama. Saboda an gwada su tare, ba za a iya tantance ko creatine, leucine, MCT, whey, resveratrol ko vitamin D ne ke haifar da tasirin ba, ko kuma suna aiki tare a matsayin haɗin ƙarfi.
Abubuwan Da Za A Iya Ɗauka A Aikace‑Aikace
Wanda Zai Iya Amfana. Manufar da ta fi dacewa ita ce manya da aka gano ko ake zargi da sarcopenia waɗanda ba za su iya yin horon ƙarfi ba, kuma su samu kulawar likita.
Abin Da Za A Duba. Ka’ida ita ce: whey da BCAAs don ƙara leucine, creatine don ƙara kuzari a tsoka, MCT a matsayin mai mai sauƙin amfani, da vitamin D3 don tallafawa tsoka da ƙashi. Takaitaccen bincike bai ba da ƙimar sinadarai ba, don haka kada a ɗauka cewa kowanne foda na kasuwa ya yi daidai da wannan tsari. Ka nemi shawarwarin likita ko ƙwararren mai abinci, musamman ga waɗanda ke da matsalar ƙoda.
Haɗa Da Horon Ƙarfi Idan Yiwuwar. Wannan gwaji ya gwada kari ba tare da horo ba, kuma ƙarfi ba ya ƙaruwa sosai. Horon ƙarfi har yanzu shine hanya mafi inganci ga sarcopenia, yayin da abinci ke ƙara mata ƙarfi. Don mutane da za su iya horo, haɗin su biyu shi ne hanya mafi kyau, ko da yake ba a gwada hakan a wannan binciken ba.
Saita Tsammani. Ka ɗauki wannan a matsayin hanya don rage raguwa da ɗan ɗaga ƙimar tsoka, ba a matsayin maganin dawo da matakin matasa ba. Makonni takwas sun samar da kimanin kilogram 0.4 na ASM, wanda ke ƙasa da ƙimar da ake ɗauka a matsayin tasiri na klinik.
Kammalawa
Wannan gwaji ya tabbatar da cewa haɗin creatine, leucine da MCT na iya ƙara ɗan tsoka a cikin manya masu shekaru 70‑80 da ba su yin horo, kuma yana da aminci a tsawon makonni takwas. Sai dai ba ya nuna cewa wannan ƙarin tsoka yana da tasiri a aikace‑aikace, kuma ƙarfi na hannu ba ya bambanta da placebo. Ana buƙatar ƙarin gwaje‑gwaje masu tsawo, tare da ƙididdiga na aiki kamar saurin tafiya da ƙirƙirar kujerar, da kuma ƙara ɓangaren horo, kafin a ɗauki wannan haɗin a matsayin magani na yau da kullum.